NASDAQ:IOVAIovance Biotherapeutics Stock Price, Forecast & News

$41.00

+2.85 (+7.47 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$37.38

Now: $41.00▼

$41.08

50-Day Range

$27.94

MA: $33.96▼

$37.79

52-Week Range

$16.12

Now: $41.00▼

$41.08

Volume1.45 million shs

Average Volume1.63 million shs

Market Capitalization$5.20 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.2

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Iovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.71, Iovance Biotherapeutics has a potential downside of 0.7% from its current price of $41.00.
Amount of Analyst Coverage
Iovance Biotherapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.2 Community Rank

Outperform Votes
Iovance Biotherapeutics has received 476 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Iovance Biotherapeutics has received 270 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Iovance Biotherapeutics has received 63.81% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote “Outperform” if you believe IOVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Iovance Biotherapeutics does not currently pay a dividend.
Dividend Growth
Iovance Biotherapeutics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.30% of the stock of Iovance Biotherapeutics is held by insiders.
Percentage Held by Institutions
95.98% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Iovance Biotherapeutics are expected to decrease in the coming year, from ($2.08) to ($2.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iovance Biotherapeutics is -22.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iovance Biotherapeutics is -22.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Iovance Biotherapeutics has a P/B Ratio of 17.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.34 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:IOVA

Previous Symbol

CUSIPN/A

CIK1425205

Webwww.iovance.com

Phone650-260-7120

Debt

Debt-to-Equity Ratio0.01

Current Ratio6.48

Quick Ratio6.48

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.37 per share

Price / Book17.30

Profitability

EPS (Most Recent Fiscal Year)($1.59)

Net Income$-197,560,000.00

Net MarginsN/A

Return on Equity-71.12%

Return on Assets-62.87%

Miscellaneous

Employees88

Outstanding Shares126,860,000

Market Cap$5.20 billion

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

How has Iovance Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IOVA stock has increased by 38.6% and is now trading at $41.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iovance Biotherapeutics?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iovance Biotherapeutics.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Iovance Biotherapeutics.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.02. View Iovance Biotherapeutics' earnings history.

What price target have analysts set for IOVA?

15 brokerages have issued 1-year price targets for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $65.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $40.71 in the next twelve months. This suggests that the stock has a possible downside of 0.7%. View analysts' price targets for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:

1. According to Zacks Investment Research, "Iovance missed estimates for earnings in Q1. Revenues were nil. Progress of the development of its two lead candidates, lifileucel and LN-145, is encouraging. The company expects to file regulatory applications seeking their approval by the end of 2020. It is also focused on expanding its pipeline through licensing and collaborations agreements. Shares of the company have significantly outperformed the industry in the past year. However, with no marketed products, the company does not generate any revenues. Moreover, the company’s pipeline candidates are at least a couple of years away from commercialization." (5/11/2020)
2. HC Wainwright analysts commented, "Our thesis on TILs stands strong. In accordance with our thesis, showing efficacy in solid tumors beyond melanoma continues to represent a game changer for Iovance and, on a broader look, we continue to view this company as a viable takeout candidate for Big Pharma. We would like to reiterate that, apart from academic-based TILs therapies such as NCI and MD Anderson, Iovance is the only biotech that is developing a commercial TIL product to treat a variety of tumors and patients using the predefined cryopreserved 22-day manufacturing strategy." (7/2/2019)

Has Iovance Biotherapeutics been receiving favorable news coverage?

Media headlines about IOVA stock have trended very positive on Monday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutIovance Biotherapeutics.

Who are some of Iovance Biotherapeutics' key competitors?

Some companies that are related to Iovance Biotherapeutics include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BioNTech (BNTX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Allogene Therapeutics (ALLO), argenx (ARGX), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA) and Ablynx (ABLYF). View all competitors.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY), Micron Technology (MU) and NVIDIA (NVDA).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:

Dr. Maria Fardis, CEO, Pres & Director (Age 51)
Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.20%), BlackRock Inc. (7.80%), Franklin Resources Inc. (4.12%), State Street Corp (3.47%), Victory Capital Management Inc. (1.57%) and Victory Capital Management Inc. (1.57%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends for Iovance Biotherapeutics.

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Wellington Management Group LLP, Victory Capital Management Inc., Victory Capital Management Inc., Alliancebernstein L.P., QVT Financial LP, Franklin Resources Inc., and Sumitomo Mitsui Trust Holdings Inc.. View insider buying and selling activity for Iovance Biotherapeutics.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Rothschild & Co. Asset Management US Inc., Lord Abbett & CO. LLC, Rice Hall James & Associates LLC, Bank of New York Mellon Corp, BlackRock Inc., Prosight Management LP, and Nuveen Asset Management LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak, and Wayne P Rothbaum. View insider buying and selling activity for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $41.00.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $5.20 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff